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Abstract A monoclonal antibody, MAb62-5, was prepared and used to detect DNA damage due to the anticancer drug cis-diamminedichloro- 
platinum (II) (or cisplatin). ELISA competition indicated that the binding of MAb62-5 to cisplatin-DNA was competitively inhibited (50% control) 
by 210 nM of cisplatin bound to DNA, cisplatin/nucleotide (D/N) = 0.2. Using a DNA mobility shift assay, MAb62-5 binding activity was inhibited 
by 50% by -50-fold molar excess of cisplatin-DNA adducts (D/N = 0.08), whereas there was less than 5% inhibition by UV-DNA adducts or 
mock-treated DNA. In addition, MAb62-5 showed a similar atfmity to the cisplatin-DNA adducts as compared to an endogenous cisplatin-damaged 
DNA recognition protein. Using ELISA with this antibody, we have demonstrated a 2-fold enhancement in excision repair of cisplatin-DNA adducts 
in resistant HeLa cells. This is supported by the measurement of repair-associated DNA strand breaks using alkaline elution and host cell reactivation 
of transfected plasmid DNA carrying cisplatin damage. These findings also provide a possible explanation for the complexicity of immunoassay in cells. 
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1. Introduction 
cis-Diamminedichloroplatinum (II), or cisplatin, is a widely 
used chemotherapeutic agent [ 1,2]. Occasionally, resistant cells 
arise during the course of treatment, hindering cancer therapy. 
It has been demonstrated that cisplatin is an effective crosslink- 
ing agent which generates various forms of cisplatm-DNA 
adducts [3]. Although the lethal target of cisplatin and the 
mechanism for the resistant phenotype are not clear, the inter- 
action of cisplatin with DNA has been implicated as the major 
cytotoxic action of the drug [4]. A number of important ques- 
tions regarding the failure of the treatment in clinics could be 
answered irectly if the extent of these DNA interactions could 
be reliably measured from small numbers of cells removed from 
patients. In the past, the majority of studies dealing with the 
quantitation of cisplatin-DNA adducts in cells involved the 
isolation of genomic DNA from treated cells, and then meas- 
urement by atomic absorption, alkaline elution, or sedimenta- 
tion. We and others have recently established an indirect 
method, i.e. host cell reactivation of damaged plasmid DNA, 
to detect DNA repair, in which cisplatin-DNA adducts are 
prepared in vitro prior to introduction into cells without mod- 
ifying the cellular repair machinery [5,6]. However, any one of 
the afore-mentioned methods is not always applicable to all 
situations. Thus, the development of a simple and sensitive 
assay is required for the detection of a low level of cisplatin- 
DNA adducts prior to the emergence of resistant phenotypes 
in cancer therapy. 
Most cisplatin-resistant cells are also resistant to alkylating 
agents and cadmium, or exhibit an alteration in their level of 
free radical scavengers like glutathione or metallothionein [3,7], 
suggesting that cisplatin resistance may be related to radical- 
mediated DNA damage and repair. Using a cell-free repair 
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system, independent investigations have demonstrated that cell 
extracts can carry out repair synthesis in DNA damaged by 
UV, psoralens and platinating agents [8-131, whereas extracts 
from some xeroderma pigmentosum (XP) cell lines are incapa- 
ble of repairing damaged plasmid DNA [8,14]. Recently, dam- 
aged-DNA binding proteins which have been identified from 
calf thymus, can complement DNA repair of XPA cell extracts 
[15], whereas cell extracts from XP group A or E cells display 
a reduced recognition of UV-damaged DNA [l&18]. These 
results suggest hat the capability of cells in eliminating dam- 
aged-DNA, largely rate-limited at the early stage of excision 
repair, plays an important role in the sensitivity or resistance 
of cells to genotoxic agents. We have previously established a 
cisplatin-resistant HeLa cell line [6], which is phenotypically 
cross-resistant to UV irradiation and overproduces damaged- 
DNA recognition proteins [9,20]. Using a cell-free system [8], 
we have demonstrated an improved recognition and incision of 
UV-DNA adducts as a potential indicator of UV resistance 
[21]. In this study, we described the production and initial 
characterization of a monoclonal antibody specific for cis- 
platin-DNA adducts. This highly sensitive and simple assay 
was compared with other methods and was used to investigate 
the accumulation of cisplatin-DNA adducts in the resistant as 
well as the parental HeLa cells. The data indicates that reduced 
adduct frequency and enhanced DNA excision repair, being 
rate-limited in the early step, are potential mechanisms of cis- 
platin resistance in human cells. The findings from the DNA 
mobility shift analysis also suggest hat the monoclonal anti- 
body preferentially recognizes cisplatin-DNA adducts, the 
same target of an endogeneous nuclear protein of cells. 
2. Materials and methods 
2.1. Media, cell cultures, and cytotoxicity 
Human cervix carcinoma HeLa cells and cisplatin-resistant HeLa- 
CPR variants [6] were maintained in a monolayer culture in Dulbecco’s 
modified Eagle’s medium (DMEM) containing 10% (v/v) fetal bovine 
serum (FBS), 100 &ml streptomycin, and 100 U/ml penicillin, and 
were incubated at 37°C in a humidified atmosphere of 5% (v/v) CO2 
in air. 1 PM cisplatin was added to the medium to maintain the resistant 
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phenotype. Prior to experiments, the resistant cells were grown contin- 
uously in media without cisplatin for three population doublings. The 
sensitivity of cells to cisplatin was determined from clonogenicity of 
cells 2 weeks following treatment. The fold resistance of cells was 
calculated by the ratio of IC,,, cisplatin concentration inhibiting 50% 
of cell proliferation, of the resistant cells vs. that of the parental HeLa 
cells. All the culture media and antibiotics were purchased from Gibco, 
Gaithersburg, MD; other chemicals were from Sigma, St. Louis, MO, 
unless otherwise indicated. 
2.2. Antibodies and enzyme-linked immunosorbent assay (ELISA) 
Monoclonal antibody MAb 62-5, which preferentially recognizes 
cisplatin-DNA adducts, was prepared according to the method of 
Sundquist et al. [22]. Briefly, calf thymus DNA (Serva) was platinated 
to bound cisplatin D/N = 0.21 as measured by atomic absorption spec- 
troscopy [23]. Exactly 0.15 mg of platinated DNA was complexed to 
methylated BSA in 0.9% NaCl, and prepared as an immunogen to 
immunize Balb/c mice. Before each cell fusion during hybrodoma 
production, blood samples were removed from the mouse tails and 
estimated for antibody activity. For ELISA of antibody activity, poly- 
styrene flat-bottomed 96-well microtiter plates (diameter 3.4 mm, Corn- 
ing) were coated with 3 pg cisplatin-DNA (calf thymus DNA) 
(D/N = 0.2) in 100~1 PBS and air-dried overnight at room temperature. 
The non-specific binding of cells was blocked by adding 1% normal 
goat serum (NGS) in PBS at 37°C for 60 min. After removal of NGS 
with PBS containing 0.05% Tween, the plate was incubated in 100 ~1 
diluted MAb 62-5 (1: 25) in the absence or presence of competitors for 
30 min at 37°C. Secondary antibody (50 pl), peroxidase-conjugated 
goat anti-mouse immunoglobulins (Dako A/S, Copenhagen, Den- 
mark), was added and incubated at 37°C for 30 min. Freshly prepared 
1 mM ABTS (2,2’-azino-bis(3-ethy(benzthiazoline-6-sulfonii acid) in 
ABTS buffer (0.1 M citrate. 0.2 M disodium nhosnhate buffer. nH 
4.2-4.8, O.Ol%‘H,O,) was then added for 30 mm and the absorbance 
at wavelength 405 nm was read with a Biotek microtiter plate reader 
as previously described [22,24,25]. 
2.3. Alkaline elution and measurement of single-stranded DNA breaks 
Single-stranded DNA breaks were estimated using alkaline elution 
as previously described [26]. Cellular DNA was labeled with 0.01 ,&W 
ml [2-Wlthymidine (51.4 Ci/mmol) or [methyl-‘Hlthymidine (25 Gil 
mmol). Following treatment of cells with cisplatin, the W-labeled cells 
were incubated for t&20 min in medium containing 10 mM hydroxyurea 
(HU) and 0.1 mM 1-/3-o-arabinofuranosyl c tosine (ara-C). ‘H-Labeled 
control cells were also incubated with the inhibitors. Cells were har- 
vested in ice-cold PBS containing 0.2 m&ml Na,EDTA. “‘C-Labeled 
cells were mixed with 3H-labeled control cells, and subjected to alkaline 
elution. The elution conditions and calculation of DNA strand breaks 
were performed as described by Rosenstein and Ducore [27]. 
2.4. DNA transfection and CAT assay 
20 pg each of pRSVcat and pSV/I (Clontech Laboratories Inc.) plas- 
mid DNA was co-transfected into cells using the electroporation tech- 
nique [28]. pRSVcat was treated with cisplatin in vitro to generate 
various extents of cisplatin-DNA adducts prior to being introduced 
into cells as described before [19]. 1 ml of the cell suspension, in HEPES 
buffer, was added to a sterile cuvette containing pRSVcat and pSV/I 
plasmid, gently mixed, and subjected to electroporation by GenePulser 
(Bio-Rad) with 1000 PF capacity and 200 V. Following 40 h incubation 
in normal medium, cells were harvested into 1 ml PBS from which 200 
pg and 400 pg of cell extracts was prepared for CAT and /.I-galactosi- 
dase activity assays [29], respectively. The CAT assay reaction was 
incubated at 37°C for 1 h, followed by development on a silica thin- 
layer chromatography (TLC) plate (Macherey-Nagel, Germany). After 
autoradiography, density on the X-ray film corresponding to the mod- 
ified chloramphenicol or not was quantitated through a scanning den- 
sitometer (Hoefer GS300). The average of three scans of each chloram- 
phenicol corresponding spot was taken. CAT activity was calculated as 
per cent of chloramphenicol substrate converted into acetylated eriv- 
atives. After being normalized to /?-galactosidase activity, relative CAT 
activity was determined by setting untreated cells as 100%. 
2.5. DNA probes, nuclear extracts, and DNA mobility shift assay 
The HindIII-EcoRI f103 fragment prepared from pGCl4 was 
treated with cisplatin or UV as previously described [18]. Briefly, 
Hind111 and EcoRI generated DNA fragments were labeled with 
[r2P]dCTP (3000 Wmmol; Amersham, Arlington Heights, IL) to 
3 x lo4 cpm/ng DNA using Klenow DNA polymerase and purified by 
column chromatography using standard methods [29]. The DNA at a 
concentration of 100 &ml was platinated according to [51] or UV 
irradiated as described before [26]. The extent ofplatination of f103 was 
estimated by atomic absorption spectroscopy as described [23]. Alter- 
natively, f103 DNA was irradiated with germicidal amps via a VL- 
1OOC UV irradiation unit (Vilbert Lourmat, France) at a fluence rate 
25 J/m’/s. The fluence rate was measured by a VLX-254 radiometer 
(Vilbert Lourmat, France). Nuclear extracts were prepared according 
to Dignam et al. [31]. The protein concentration was measured via the 
Bradford assay using the Bio-Rad dye reagent [32], and visualized by 
SDS-PAGE [33]. Protein-DNA binding was performed according to 
Hannighausen and Lubon [34] using antibody MAb62-5 (1 : 25 dilution) 
or nuclear extracts in a 15 ~1 of buffer containing 12% glycerol 12 mM 
HEPES (pH 7.9), 100 mM KCl, 5 mM MgCl,, 4 mM Tris-HCl, 1 mM 
EDTA, 1 mM dithiothreitol, 300 &ml BSA and 2 pg poly(dI-dC) at 
25°C for 30 min as described. The reaction mixtures were then sub- 
jected to 5% polyacrylamide gel electrophoresis under low ionic 
strength (6.7 mM Tris-HCl, pH 7.9, 3.3 mM sodium acetate, 1 mM 
EDTA) at 30°C and 15 mA constant current. The resolved gel was dried 
and exposed to Kodak XAR-5 X-ray film with an intensifying screen 
at -70°C. The intensity of the shifted DNA bands was determined from 
the average of three scans by scanning densitometry. 
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Fig. 1. Specificity of MAb62-5 as assayed by ELISA. (Upper panel) 
Dose-response of MAb62-5 binding. The line was calculated by-linear 
renression as v = 0.067345 +0.68047. LOG(x): R* = 0.928. where R is 
the correlation coefficient. (Lower panel) Competition of MAb62-5 
binding. The indicated amounts of competitors, untreated or cisplatin- 
treated double-stranded (ds) DNA adducts (D/N = 0.2), were added to 
the binding reaction. 
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3. Results 
3.1. Specificity of the monoclonal ntibody 
The specificity of MAb62-5 (1: 25 dilution) was characterized 
in vitro by ELISA (Fig. 1). Exactly 0, 10, 50, 100 or 200 ng of 
platinated DNA (D/N = 0.2) was used to generate a dose- 
response curve (Upper Panel). The ODa5 nm increased with the 
amount of cisplatin-DNA, giving a regression line with a slope 
of 0.68047. For competition analysis, a 96-well plate was coated 
with platinated DNA (D/N = 0.2). Exactly 0, 10, 50, 100 or 200 
ng of untreated or platinated DNA was used as competitor. The 
competition curves were determined by the OD,,“, vs. the 
amount of competitor (Fig. 1, lower panel). Apparently, con- 
trol DNA (open symbols) did not affect MAb binding. In con- 
trast, more than 50% of the binding was inhibited by 10 ng 
or more cisplatin-DNA (filled symbols). For comparison, com- 
petitors other than cisplatin-treated DNA were also ana- 
lyzed. The IC,, values derived from the competition curves 
were determined (Table 1). Cisplatin-treated ssDNA or 
poly(dG).poly(dC) with indicated D/N, respectively, displayed 
17- and lOO-fold less effective inhibition than the cisplatin- 
treated dsDNA. About 300 fold of transplatin-treated sDNA 
or ssDNA was needed to inhibit the same level of immunoreac- 
tivity. Additionally, the specificity of MAb62-5 in a 1: 50 dilu- 
tion generated similar results. 
Cellular specificity of MAb62-5 was also demonstrated by 
competitive ELISA (Fig. 2). DNA from cells treated with 0, 15, 
50 or 150 PM cisplatin was isolated and the relative OD,, ,,,,, 
was determined. In all these assays in which 50% binding was 
inhibited by - 10 fold competitor the competition patterns were 
similar or the same. As shown, more than 90% binding was 
inhibited by 100 fold competitor. Compared with untreated 
cells, a - lo’, lo6 and 10’ fold difference in the amount of com- 
petitor is required to inhibit 50% binding in cells treated with 
15, 50 and 150 PM cisplatin, respectively. The level of DNA 
adducts determined by atomic absorption spectrophotometry 
in 15 PM cisplatin-treated HeLa and a derivative cell line is - 890 
and 340 nmol cisplatin per g of DNA, respectively [35]. Using 
ELISA, induced DNA adducts were also detected in 5 ,uM 
cisplatin-treated cells (data not shown). The results indicate 
that MAb62-5 preferentially interacts with cisplatin-DNA ad- 
ducts in vitro and in vivo. 
3.2. Detection of MAb62-5 binding activity by DNA mobility 
shift assay 
MAb62-5 binding activity was detected by DNA mobility 
shift assay (Fig. 3). Under the standard DNA-binding condi- 
Table 1 
Immunoreactivity of MAb62-5 measured by ELISA 
Competitor” D/IV lc,, (ngY 
Cisplatin-dsDNA 0.21 7 
Cisplatin-ssDNA 0.14 120 
Transplatin&DNA 0.42 2500 
Transplatin-ssDNA 0.49 2000 
“ssDNA, single-stranded DNA prepared by boiling dsDNA for 10 min 
and rapid cooling at 4’C. 
bD/N, competitor DNA at bound platinum/nucleotide ratio as deter- 
mined by atomic absorption spectroscopy [23]. 
‘Amounts of platinated DNA which caused 50% inhibition of the 
binding. 
- 0 150pM 
A 5OpM 
0 15pM 
l untreated 
* oI,.._.~ 
10010' 102 103 104105 10510710~10Q 
Competitor (ng) 
Fig. 2. Competitive ELISA for DNA extracted from cells that had been 
exposed to cisplatin. DNA extracted from cells treated with cisplatin 
at indicated concentrations for 5 h, assayed by ELISA. Points, mean 
readings from three wells; bars indicate S.E.M. S.E.M. lie within sym- 
bols unless shown by bars). 
tions with MAb62-5 at 1: 25 dilution, in the absence (lane 2) or 
presence of lo-fold (lanes 4,6 and 8) or lOO-fold (lanes 5, 7 and 
9) of indicated competitors, a binding activity was detected 
(indicated with an arrowhead). MAb62-5 binding activity was 
inhibited by -30% by a lOO-fold fl03-pt, whereas greater han 
90% binding was inhibited by a lOOO-fold fl03-pt. In contrast, 
the binding remained intact with either 100 or 1000 fold f103 
or fl03-uv. As also shown, an additional binding band was 
detected by undiluted MAb62-5 (lane 3). The latter was proba- 
bly due to interaction of a platinated DNA with more than one 
antibody molecule since D/N = 0.08 corresponds to -10 cis- 
platin per f103. Reaction with probe alone showed only free 
probe (indicated with a star) and non-specific binding. Thus, 
the immunoreactivity of MAb62-5 could be detected in a DNA 
mobility shift assay. 
3.3. Similarity in the binding pattern of MAb62-5 and CDRP 
The endogenous nuclear proteins of cells which recognize 
cisplatin-DNA adducts (i.e. CDRP) have previously been iden- 
tified by DNA mobility shift assay [20]. Competition patterns 
of MAb62-5 and CDRP binding activities were compared (Fig. 
4A). Binding competition using 8 pg of nuclear extracts in the 
absence (lanes 2-7) or presence (lanes 8-13) of MAb62-5 was 
conducted. CDRP binding (indicated with an arrow) decreased 
with increasing amounts of competitor fl03-pt: 0, 10, 100 and 
1000 fold (lanes 2-5, respectively). Approximately 50-60% 
binding was inhibited by a 100 or 1000 fold competitor. In 
contrast, 1000 fold of f103 or fl03-uv did not inhibit, or only 
slightly affected, CDRP binding (lanes 6 and 7, respectively). 
In the presence of MAb62-5, the competition pattern of the 
CDRP binding activity was essentially not affected. Under this 
condition (1 ng fl03-pt, D/N = 0.08) the competition of the 
MAb62-5 binding (indicated with an arrowhead) was also unaf- 
fected by CDRP. Neither binding activities were inhibited by 
f103 or fl03-uv (lanes 12 and 13). The binding activities 
MAb62-5 and CDRP were calculated (Fig. 4B). The relative 
binding of MAb62-5 (Ab), CDRP alone (-) or together with 
MAb62-5 (+) appeared to be similar. The IC,,, i.e. molar excess 
competitor causing 50% inhibition, was 50-60 for each case. 
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3.5. Demonstration of enhanced repair in the resistant cells by 
indirect methods 
To further evaluate results obtained by immunoassays, DNA 
repair in the resistant and the parental cells was measured by 
conventional methods (Table 2). The slopes for HeLa and 
HeLa-CPR cells obtained from the immunoassay were 0.0057 
and 0.0028, respectively. The estimated enhancement of DNA 
repair was 2.04 fold. For alkaline elution [26], cells were treated 
with 50 PM cisplatin for 5 h, incubated for 24 h, and repair- 
associated DNA strand breaks were measured. The excess 
A) 
Ab + 
123456789 
Fig. 3. Binding of MAb62-5 to cisplatin-DNA adducts as measured by 
DNA mobility shift assay. Exactly 1 ~1 of MAb62-5 at 1: 25 dilution 
in the absence (lane 2) or presence of competitor, fl03-pt (D/N = 0.08), 
f103 or fl03-UV (6000 J/m?, was incubated with 1 ng of DNA probe 
fl03-pt (D/N = 0.08). Lane 1, probe alone; lane 3, MAb62-5 without 
dilution. The comnetitors are in 100 fold (lanes 4.6 and 8) or 1000 fold 
molar excess (lanes $7 and 9). *Free probe; arrowhead, bound probe. 
camp, competitor. 
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3.4. Reduced accumulation of cisplatin-DNA adduct in the 
resistant cells 
A comparison of the removal kinetics of cisplatin-DNA ad- 
ducts between HeLa-CPR and the parental HeLa cells was 
done using the ELISA assay (Fig. 5). HeLa and HeLa-CPR 
cells were treated, respectively, with 50 and 200 PM cisplatin 
for 5 h, and the amount of cisplatin-DNA adducts was meas- 
ured by ELISA at 0,4, 12 or 24 h after cisplatin treatment (Fig. 
5, upper panel). It should be noted that these cisplatin concen- 
trations caused 37% survival of each of the cell lines as deter- 
mined by colony forming assay. Both repair patterns showed 
a slight increase, with a peak accumulation at 4 h followed by 
a decrease in the relative OD,, Om. Cisplatin-treated resistant 
and parental cells with a similar peak accumulation of cis- 
platin-DNA adducts exhibited a nearly identical kinetic pat- 
tern following repair incubation. When both cell lines were 
treated with 50 PM cisplatin, the patterns were similar. How- 
ever, the relative OD,, nm of HeLa-CPR cells is _ 50% less than 
that of HeLa cells (data not shown). The data indicated that 
the removal rate of cisplatin-DNA adducts was the same in 
both cell lines. The dose-response curve was also determined 
(Fig. 5, lower panel). Cells were treated with 0,25, 50,75 or 150 
PM of cisplatin. Following 5 h of incubation, the level of cis- 
platin-DNA adducts in cells was analyzed. There was a linear 
correlation (with indicated regression coefficient R) within 
these concentrations of cisplatin in both cells. The regression 
lines of the dose-responses were indicated with slopes of 0.0057 
and 0.00276 for HeLa and HeLa-CPR cells, respectively, indi- 
cating a - 2 fold enhancement of DNA repair in HeLa-CPR cells. 
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Fig. 4. Binding of nuclear extracts to cisplatin-DNA adducts. 
(A) Binding of 8 pg of nuclear extracts in the absence (lanes 2-7) or 
presence (lanes 8-13) of MAb62-5 (1~1 at 1: 25 dilution). The binding 
reaction was conducted without (lanes 2 and 8) or with increasing 
amounts of competitor: 10, 100, and 1000 fold fl03-pt (D/N = 0.2) 
(respectively for lanes 3-5 and lanes 9-l l), 1000 fold f103 (lanes 6 and 
12) or 1000 fold fl03-uv (lanes 7 and 13). *Free probe; arrowhead, 
MAb62-5 bound probe; arrowhead, nuclear extracts bound probe. 
camp, competitor. (B) Quantitation of binding competition. Relative 
adduct binding vs. fold competitor was estimated by scanning den- 
sitometry of the intensity of the bound probe (data derived from A). 
CDRP(-), nuclear extract binding in the absence of MAb62-5; 
CDRP(+), nuclear extract binding in the presence of MAb62-5. Ab, 
MAb62-5 binding. 
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Fig. 5. Repair of cisplatin-DNA adducts in HeLa and HeLa-CPR cells 
as measured by ELISA. (Upper panel) Repair kinetics following cis- 
platin treatment. Cells were treated with cisplatin (50 and 200 PM for 
HeLa and HeLa-CPR cells, respectively) for 5 h to accumulate an equal 
level of cisplatin-DNA adducts, and incubated in drug-free culture 
medium for various times prior to the assay. The 0D405nm 
(mean f SD.) (a = 3) of tested vs. untreated cells is shown. (Lower 
panel) Dose-response of cisplatin-DNA adduct accumulation. Cells 
were treated with various concentrations of cisplatin for 5 h, incubated 
for 24 h, and the relative OD,, nm was determined. The lines were 
calculated by linear regression as y = 0.39809 + 0.0056983x; R2 = 0.952 
(HeLa) and y = 0.31225 + 0.0027624x; R* = 0.905 (HeLa-CPR), where 
R is the correlation coefficient. 
DNA strand breaks of HeLa and HeLa-CPR cells vs. incuba- 
tion time were determined. There were - 1.6 excess strand breaks 
(ESB) per 10” Da of HeLa DNA following a 1 min incubation 
as compared to -3.1 breaks under the same assay conditions in 
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HeLa-CPR cells. The slopes of the regression curves were 0.99 
and 0.516 for the resistant and the parental cells, respectively, 
indicating a 1.92 fold enhancement of the repair rate in HeLa- 
CPR cells. DNA repair in the resistant and the parental cells 
was also measured by plasmid reactivation, an indirect meas- 
urement of DNA excision repair [6]. Plasmid DNA pRSVcat 
with D/N = 0, 0.001, 0.002, or 0.004 was co-transfected with 
un-treated pSVp for transient expression. The CAT and p- 
galactosidase activities were measured 40 h after transfection. 
The ICso, i.e. cisplatin concentration inhibiting 50% CAT activ- 
ity, for HeLa and HeLa-CPR cells were D/N = 0.0007 and 
0.0015, respectively. The I&,, as determined by the plasmid 
reactivation assay for HeLa and HeLa-CPR cells, corre- 
sponded to -3.5 and 7.5 cisplatin per plasmid, respectively. 
There was a -2.1 fold enhancement of the plasmid reactivation 
in the resistant cells. Thus, the enhanced DNA repair in HeLa- 
CPR cells, as measured by our immunoassay, is comparable to 
the results obtained by conventional methods. 
4. Discussion 
In this study, a monoclonal antibody was prepared for the 
measurement of cisplatin-DNA adducts. According to the 
competition pattern of ELISA, in vitro, 50% of MAb62-5 bind- 
ing was inhibited by 7 ng of competitor (Fig. l), which corre- 
sponded to 0.21 PM in a typical 100 ~1 reaction (1 pg/ml = 
3 PM). Competitive ELISA in vivo demonstrated that MAb62- 
5 preferentially interacted with cisplatin-DNA adducts. Im- 
munofluorescence microscopy analysis also indicated that the 
antibody was specific to the nucleus, but not he cytosol, in cells 
treated with cisplatin (data not shown). Using cisplatin-DNA 
(D/N = 0.03) as an immunogen, Lippard and co-workers re- 
ported a monoclonal antibody the binding activity of which was 
inhibited by 4-6 nM (50% inhibition) but appeared to be insuf- 
ficiently sensitive for biologial experiments [22]: it was 42 fold 
less sensitive in MAb62-5 immunoreactivity. In an in vivo 
study, Tilby et al. [35] demonstrated an immunoassay in Walker 
tumor cells based upon a monoclonal antibody that enabled the 
quantitation of cisplatin-DNA adducts down to 3 mnol cis- 
platin/g DNA (i.e. 1 cisplatin adduct/106 bases). We also de- 
tected DNA adducts from 15 PM cisplatin-treated HeLa cells, 
which corresponded to 342.48 nmol cisplatin/g DNA or 8.8 
cisplatin adduct/103 bases, determined by atomic absorption 
spectrophotometry [35]. Furthermore, DNA adducts could 
also be detected from cells treated with 5 ,uM cisplatin (210 
nmol cisplatin/g DNA or 1.4 adducts/104 bases). This value was 
-70 fold lower than that reported by Tilby et al. [36].,Although 
we did not measure the low limit of MAb62-5 sensitivity, it is 
Table 2 
Comparison of DNA repair measured by different methods in HeLa and the resistant HeLa-CPR cells 
HeLa HeLa-CPR Fold alterationd 
Immunoassay (AFF) 0.0057 f 0.0006 0.0028 f 0.0004 2.04 
Alkaline elution (ESB)b 0.516 + 0.051 0.99 f 0.1 1.92 
Plasmid reactivation, IC, (D/N) 0.0007 * 0.00012 0.0015 * 0.0003 2.14 
“The data were expressed as AFF f S.D. (n = 3). AFF, average adduct formation frequency, detined by OD,, _/PM cisplatin as assayed by ELISA 
(also see Fig. 2). The background AFF has been substracted from the values shown. 
“The data were expressed as ESB f S.D. (n = 3). ESB, average xcess strand breaks, per 10”’ nucleotides genomic DNA per min incubation. 
‘The data were expressed as IC,, f SD. (n = 3), estimated cisplatin-DNA adducts (D/N) required to inhibit 50% CAT activity, as assayed by plasmid 
reactivation. 
d Fold alteration was calculated as fold decrease in immunoassay, and fold increase in alkaline elution and plasmid reactivation assays. 
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probably similar to the previously reported antibody [36]. If 
MAb62-5 showed reduced sensitivity, it could be explained by 
the suggestion that an immunogen with a high level of D/N 
modification causes low efficiency in detection [37]. This is 
supported by the preparation of a monoclonal antibody with 
good sensitivity for cisplatin-DNA adducts using lowered cis- 
platin/DNA as an immunogen [38]. In this study, we have 
demonstrated the feasibility of using MAb62-5 to differentiate 
cisplatin-DNA adducts accumulated in the resistant and the 
parental cells. The data was consistent with measurement by 
alkaline elution and plasmid reactivation assays. Enhanced 
DNA repair detected in HeLa-CPR cells suggested a causative 
mechanism(s) for the resistant phenotype. The kinetic pattern 
of the accumulation of cisplatin-DNA adducts in the resistant 
cells is the same as in the parental cells except that the initial 
level of cisplatin-DNA adducts is 50% lower. Therefore, the 
reduced frequency of adduct formation plays a major role in 
the overall enhancement of DNA repair in the resistant cells. 
To verify the possible genetic alterations, a revertant subline, 
HeLa-rev, derived from HeLa-CPR, was characterized [39]. 
The IQ0 of DNA repair using the immunoassay as described 
above was 0.0039, giving a 1.2 fold increase in DNA repair 
compared to HeLa cells. The results suggested that the pheno- 
typic change in resistance was due to a simple mutation. We 
have previously demonstrated that the cross-resistance of 
HeLa-CPR cells to UV damage is associated with enhanced 
recognition and incision of UV-DNA adducts in a cell-free 
system [21]. Current studies have demonstrated the improved 
excision repair of cisplatin-DNA adducts in the resistant cells, 
which is also largely determined by the early stage of the repair 
process. Since reduced repair synthesis in XP group A cells has 
been assigned to the incision step [40], our resistant cells have 
most likely acquired an enhanced DNA repair that is deficient 
in the XP cells. 
The specificity of MAb62-5 was also confirmed by the DNA 
mobility shift assay in vitro. 50% inhibition of the MAb62-5 
binding required 50 fold platinated-DNA competitor, whereas 
less than 5% binding was inhibited by 1000 fold UV-irradiated 
DNA. Interestingly, it showed a similar affinity to platinated 
DNA between the antibody and the endogenous cisplatin DRP 
in cells. In contrast, 50% inhibition of the UVDRP binding 
activity required only -20 fold excess of specific ompetitor [41]. 
Therefore, MAb62-5 as well as cisplatin DRP distinguishes 
ciplatinum modification from UV modification of the same 
DNA molecule. The sensitive detection of cisplatin-DNA ad- 
ducts in vivo using monoclonal antibody has also been demon- 
strated by others [36]. Assays with apparently reduced sensitiv- 
ities at low DNA modification levels have been described for 
other types of DNA damage [4244]. This may be partly ex- 
plained by the presence of CDRP in cells, which potentially 
competes with the antibody. As demonstrated in this study, 
MAb62-5 showed a similar affinity to the HeLa CDRP for 
cisplatin-modified plasmid DNA, suggesting that the binding 
domain of MAb62-5 is homologous to that of CDRP. It is likely 
that a low level of cisplatin-DNA adducts in the cellular chro- 
mosome is bound by endogenous CDRP prior to assessment 
and not by the antibody during immunochemical detection. 
However, one may underestimate the amount of cisplatin- 
DNA adducts using immunoassay due to competitive pre-occu- 
pation by endogenous CDRP. Therefore, one should be cau- 
tious when comparing cisplatin-DNA repair between different 
C.C.-K. Chao et al. IFEBS Letters 354 (1994) 103%109 
cell lines using the immunoassay because variation of CDRP 
in cells may complicate the immunochemical detection. Auxil- 
iary to this is the underestimation of cisplatin-DNA adducts 
using antibody in cells harboring a high CDRP level. The sim- 
ple DNA mobility shift assay of CDRP in vitro is informative 
in evaluating the in situ detection of cisplatin-DNA adducts 
using antibodies. The same strategy may be applied to explain 
the complexicity using the immunoassay for other DNA ad- 
ducts such as UV-damaged DNA. 
Acknowledgements: This work was supported in part by research grants 
from Chang Gung Medical College (CMRP 388) and the National 
Science Council, ROC (NSC82-0412-Bl82-017-MO2 to C.C.-K.C. and 
NSC81-0211-B007-06 to H.H.). 
References 
[1] Loehrer, P. and Einhorn, L.H. (1984) Cisplatin. Ann. Intern. Med. 
100, 704-713. 
[2] Rosenberg, B. (1985) Cancer (Phila.) 55, 2303-2316. 
[3] Hospers, G.A.P., Mulder, N.H. and De Vries, E.G.E. (1988) Med. 
Oncol. Tumor Pharmacother. 5, 145-151. 
[4] Roberts, J.J. and Thomson, A.J. (1979) Prog. Nucleic Acid Res. 
Mol. Biol. 22, 71-133. 
[5] Chu, G. and Berg, P. (1987) Mol. Biol. Med. 4, 277-290. 
[6] Chao, C.C.-K., Lee, Y.-L., Cheng, P.-W. and Lin-Chao, S. (1991) 
Cancer Res. 51, 601605. 
[7] Eastman, A. and Richon, V.M. (1986) in: Biochemical Mecha- 
nisms of the Platinum Antitumor Drugs (McBrien, D.C.H. and 
Slater, T.F., eds.) pp. 91-l 19, IRL Press, Oxford, England. 
[8] Wood, R.D., Robins, P. and Lindahl, T. (1988) Cell 53, 97-106. 
[9] Wood, R.D. (1989) Biochemistry 28, 8287-8292. 
[lo] Hansson, J. and Wood, R.D. (1989) Nucleic Acids Res. 17,8073- 
8091. 
[11] Sibghat-Ullah, Husain, I., Carlton, W. and Sancar, A. (1989) Nu- 
cleic Acids Res. 17, 44714484. 
[12] Sibghat-Ullah and Sancar, A. (1990) Biochemistry 29,571 l-5718. 
1131 Hansson. J.. Munn, M., Rupp, W.D., Kahn, R. and Wood, R.D. . - 
(1989) J. Biol. Chem. 264, 21788-21792. 
[14] Hansson, J., Keyse, SM., Lindahl, T. and Wood, R.D. (1991) 
Cancer Res. 51, 33843390. 
[I51 
[I61 
1171 
V81 
[I91 
PO1 
WI 
P21 
~231 
[241 
~251 
WI 
~271 
Robins, P., Jones, C.J., Biggerstaff, M., Lindahl, T. and Wood, 
R.D. (1991) EMBO J. 10, 3913-3921. 
Chu, G. and Chang, E. (1988) Science 242, 564-567. 
Kataoka, H. and Fujiwara, Y. (1991) Biochem. Biophys. Res. 
Commun. 175, 1139-1143. 
Chao, C.C.-K. (1992) Biochem. J. 282,203-207. 
Chao, C.C.-K., Huang, S.-L., Huang, H.-M. and Lin-Chao, S. 
(1991) Mol. Cell. Biol. 11, 2075-2080. 
Chao. C.C.-K.. Huang, S.-L., Lee, L.-Y. and Lin-Chao, L.-Y. 
(1991) Biochem. J. 277, 8755878. 
Chao. C.C.-K. and Huanc. S.-L. (1993) Mutat. Res. 303. 19-27. 
Sundquist, W.I., Lippard,x.J. and‘Stoll&, B.D. (1987) Proc. Natl. 
Acad. Sci. USA 84, 8222-8229. 
Skoog, D.A. and Leary, J.J. (1992) in: Principles of Instrumental 
Analysis, pp. 21 l-223, Holt Saunders, Philadelphia. 
Poirier, M.C., Lippard, S.J., Zwelling, L.A., Ushay, H.M., 
Kerrigan, D., Thill, CC., Santella, R.M., Grunberger, D. and 
Yuspa, S.H. (1982) Proc. Natl. Acad. Sci. USA 79, 6443-6447. 
Malfoy, B., Hartmann, B., Macquet, J.P. and Leng, M. (1981) 
Cancer Res. 41, 41274131. 
Chao, C.C.-K. and Rosenstein, B.S. (1986) Photobiochem. Photo- 
biol. 43, 165-170. 
Rosenstein, B.S. and Ducore, J.M. (1983) Photochem. Photobiol. 
38, 51-55. 
[28] Chu, G., Hayakawa, H. and Berg, P. (1987) Nucleic Acids Res. 15, 
1311-1326. 
[29] Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989) Molecular 
Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, 
Cold Spring Harbor, New York. 
[30] Ushay, H.M., Tullius, T.D. and Lippard, S.J. (1981) Biochemistry 
20, 37443748. 
Dignam, J.D., Lebovitz, R.M. and Roeder, R.G. (1983) Nucleic 
Acids Res. 11, 1475-1489. 
[32] Bradford, M.M. (1976) Anal. Biochem. 72, 248-254. 
[33] Lammli, U.K. (1970) Nature 227, 680-685. 
[34] Haunnighausen, L. and Lubon, H. (1987) Methods Enzymol. 152, 
721-735. 
[35] Chao, C.C.-K. (1994) Mol. Pharmacol. 45, 1137-l 144. 
[36] Tilby, M.J., Johnson, C., Knox, R.J., Cordell, J., Roberts, J.J. and 
Dean, C.J. (1991) Cancer Res. 51, 123-129. 
[37] Fichtinger-Schepman, A.-M.J., Baan, R.A. and Berends, F. (1989) 
Carcinogenesis 10, 2367-2369. 
[38] Terheggen, P.M.A.B., Floot, B.G.J., Scherer, E., Begg, A.C., 
Fichtinger-Schepman, A.-M.J. and Den Engelse (1987) Cancer 
Res. 47, 6719-6725. 
1391 Chao, CC-K. (1994) Eur. J. Pharmacol. (in press). 
[40] Cleaver, J.E. and Kraemer, K.H. (1989) in: The Metabolic Basis 
of Inherited Disease (Striver, CR., Beaudet, A.L., Sly, W.S. and 
Valle, D., eds.) pp. 2949-2971, McGraw-Hill, New York. 
[41] Chao, C.C.-K., Huang, S.-L. and Lin-Chao, S. (1991) Nucleic 
Acids Res. 19, 6413418. 
[42] VanSchooten, F.J., Kriek, E., Steenwinkel, M.-J.S.T., Noteborn, 
H.P.J.M., Hillebrand, M.J.X. and Van Leeuwen, F.E. (1987) 
Carcinogenesis 8, 1263-1269. 
[43] Santella, R.M., Weston, A., Perera, F.P., Trivers, G.T., Harris, 
C.C., Young, T.L., Nguyen, D., Lee, B.M. and Poirier, M.C. 
(1988) Carcinogenesis 9, 1265-1269. 
[44] West, G.J., West, I.W.-L. and Ward, J.F. (1982) Radiat. Res. 90, 
595-608. 
